Cassava Insiders Got A Lot Richer As Shares Rebound Following Refutation of Data Manipulation Claims

Journal of Prevention of Alzheimer's Disease (JPAD) informed Cassava Sciences Inc SAVA about no convincing evidence to support data manipulation allegations in a 2020 paper on simufilam co-authored by the company's personnel and its science collaborators.
Simufilam, Cassava's Alzheimer's candidate, is a small molecule (oral) drug that restores the normal shape and function of altered filamin A protein in the brain.
"From the onset, I have said that allegations of research misconduct are false, and for a good reason – I see no supporting evidence for the allegations," said Remi Barbier, President & CEO.
"I'm hopeful that written pronouncements from neutral and independent science experts will help close the chapter of baseless attacks against our science."
Related Content: Cassava Sciences Shares Plunge After Criminal Investigation Report.
In May 2022, Neurobiology of Aging investigated and found no evidence of data manipulation in a paper on simufilam published in that journal in 2017.
In December 2021, Cassava Sciences announced that Neuroscience investigated and found no evidence of data manipulation in a paper published in 2005.
In November 2021, Cassava Sciences announced that The Journal of Neuroscience investigated and found no evidence of data manipulation in a paper on simufilam published in July 2012.
Price Action: SAVA shares are up 1.79% at $26.18 on the last check Thursday.